Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1682—Processes
  • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Definitions

• the invention relates to the field of pharmacology and, in particular, to sustained-release particles for parenteral administration of active pharmaceutical ingredients.
• the invention also relates to methods for preparing such particles containing an active pharmaceutical ingredient.
• a pharmaceutical agent be administered in a sustained-release formulation, often to achieve a nearly constant or pseudo-zero- order release rate over a significant period of time and to reduce the problems associated with previous administration methods.
• problems include poor bioavailability, first pass metabolism, non-compliance or non-adherence to therapy, and reducing the opportunity for sequestering drug tablets for illegal use.
• the production and use of pharmaceutical preparations including larger drug particles to sustain delivery have been described in the art for certain antibiotics, insulin, and steroids (see, e.g., Ansel, Allen and Popovich, eds., Pharmaceutical Dosage Forms and Drug Delivery Systems. 7 th Edition, Lippincott Williams & Wilkins, Philadelphia, PA, 1999; Gennaro ed., Remington: The Science and Practice of Pharmacy. 19th Edition, Lippincott Williams & Wilkins, Philadelphia, PA, 1995)).
• sustained release systems employ a finely milled or micronized preparation of the active pharmaceutical ingredient as a starting point in the formulations.
• the release of the active pharmaceutical ingredient into the body is then controlled using matrices, membranes or other inactive ingredients or devices.
• matrices, membranes or other inactive ingredients or devices examples include liposomes, bioerodable matrices (e.g., PLA/PGLA matrices), drug-permeable implants (e.g., U.S. Pat. No. 3,993,073 to Zaffaroni), implants with drug-permeable and drug-impermeable membranes (e.g., U.S. Pat. No.
• Penicillin G and V have been formulated as a sustained release injection by complexing the penicillin molecule with procaine or with benzathine. Suspensions of crystals of benzathine and procaine penicillin can be useful in the treatment of rheumatic fever and other infections. Typically, therapeutic levels of these antibiotics can be sustained for 14-28 days after a single BVI injection (Cadomiga et al. (1991), Eur. J. Drug Metab. Pharmacokinet. 3:379-84; Kaplan et al. (1989), J. Pediatr.
• the present invention depends, in part, upon the development of coated microparticles which permit the release of an active pharmaceutical ingredient over an extended or sustained-release period of time after parenteral administration.
• the coated microparticles of the invention provide for sustained-release with improved kinetics, including approximately constant or pseudo-zero-order kinetics, over the sustained-release period.
• the inventions provides a pharmaceutical preparation for sustained-release of an active pharmaceutical ingredient after parenteral administration which includes a multiplicity of coated microparticles which include the active pharmaceutical ingredient, and a first polymeric coating formed from a first polymer-forming solution.
• the active pharmaceutical ingredient forms a saturated solution within the coated microparticles after administration, and the first polymeric coating is permeable to the active pharmaceutical ingredient during the sustained- release period from administration of the microparticles until the concentration of the active pharmaceutical ingredient contained within the microparticles is unsaturated.
• the invention provides coated microparticles which further include a second polymeric coating on the first polymeric coating, wherein the second polymeric coating is formed from a second polymer-forming solution and is permeable to the active pharmaceutical ingredient during the sustained-release period.
• the invention provides coated microparticles which further include a porous second polymeric coating on the first polymeric coating, wherein the second polymeric coating is formed from a second polymer-forming solution, wherein the second polymeric coating defines pore regions which permit fluid communication between a pore portion of the first polymeric coating and the external environment, thereby allowing diffusion of the active pharmaceutical ingredient across the first polymeric coating in the pore regions, and wherein the second polymeric coating defines non-pore regions which prevent fluid communication between a non-pore portion of the first polymeric coating and the external environment, thereby inhibiting diffusion of the active pharmaceutical ingredient across the first polymeric coating in the non-pore regions.
• the second polymeric coating is substantially impermeable to the active pharmaceutical ingredient in said non-pore regions.
• the second polymer-forming solution includes pore-forming agents which dissolve to produce the pore regions after formation of the second polymeric coating.
• the invention provides methods of sustained-release administration of an active pharmaceutical ingredient by administering parenterally a pharmaceutical preparation of the coated microparticles of the invention.
• the pharmaceutical preparation is in the form of a suspension of the coated microparticles in a pharmaceutically acceptable carrier.
• parenteral administration is subcutaneous, intravenous, intramuscular or intraocular injection.
• the invention provides methods for producing a pharmaceutical preparation for sustained-release of an active pharmaceutical ingredient after parenteral administration.
• the methods include forming core particles including the active pharmaceutical ingredient, and forming a first polymeric coating on the core particles from a first polymer-forming solution, wherein the active pharmaceutical ingredient forms a saturated solution within the coated microparticles after administration, and wherein the first polymeric coating is permeable to the active pharmaceutical ingredient during a sustained-release period from administration of the microparticles until the concentration of the active pharmaceutical ingredient contained within the microparticles is unsaturated.
• the methods further include the step of forming a second polymeric coating on the first polymeric coating from a second polymer-forming solution, wherein the second polymeric coating is permeable to the active pharmaceutical ingredient during the sustained-release period.
• the methods further include the step of forming a porous second polymeric coating on the first polymeric coating from a second polymer- forming solution, wherein the second polymeric coating defines pore regions which permit fluid communication between a pore portion of the first polymeric coating and the external environment, thereby allowing diffusion of the active pharmaceutical ingredient across the first polymeric coating in the pore regions, and wherein the second polymeric coating defines non-pore regions which prevent fluid communication between a non-pore portion of the first polymeric coating and the external environment, thereby inhibiting diffusion of the active pharmaceutical ingredient across the first polymeric coating in the non-pore regions.
• the second polymeric coating is substantially impermeable to the active pharmaceutical ingredient in the non-pore regions.
• the second polymer-forming solution comprises pore-forming agents which dissolve to produce the pore regions after formation of the second polymeric coating.
• diffusion of the active pharmaceutical ingredient across the first polymeric coating exhibits pseudo-zero-order kinetics during the sustained- release period.
• the first polymeric coating is substantially degraded after the sustained-release period. In addition, in some embodiments, the first polymeric coating maintains structural integrity during the sustained-release period. In some embodiments, the microparticles have a maximum dimension between 20 ⁇ m and 800 ⁇ m, between 40 ⁇ m and 400 ⁇ m, or between 100 ⁇ m and 250 ⁇ m.
• the active pharmaceutical ingredient is substantially insoluble in the first polymer-forming solution. In some embodiments, the active pharmaceutical ingredient is hydrophobic and the first polymer-forming solution is hydrophilic. In other embodiments, the active pharmaceutical ingredient is hydrophilic and the first polymer-forming solution is hydrophobic.
• the first polymeric coating and/or the second polymeric coating includes a material selected from the group consisting of naturally occurring polymers, including carbohydrates such as sugar phosphates, alkylcelluloses (e.g., ethylcellulose), and hydroxyalkylcelluloses (e.g., hydroxypropylcellulose); and synthetic polymers or co-polymers, including one or more of the following monomers: lactic acid, glycolic acid, ⁇ -propiolactone, ⁇ -butyrolactone, ⁇ -butyrolactone, pivalolactone, ⁇ -hydroxy butyric acid, ⁇ -hydroxyethyl butyric acid, ⁇ -hydroxy isovaleric acid, ⁇ -hydroxy- ⁇ -methyl valeric acid, ⁇ -hydroxy caproic acid, ⁇ -hydroxy isocaproic acid, ⁇ -hydroxy heptanic acid, ⁇ -hydroxy octanic acid, ⁇ -hydroxy decanoic acid, ⁇ -hydroxy myristic acid, ⁇ -hydroxy
• the first polymeric coating is applied to the core particles by an air suspension technique. In other embodiments, first polymeric coating is applied to the core particles by a dip coating technique.
• the weight of the polymeric coating(s) is between 0.1% and 200% of the weight of the core particle. In other embodiments, the weight of the polymeric coating(s) is between 2% and 60% of the weight of the core particle. In some embodiments, the volume of the polymeric coating(s) is between
• the volume of the polymeric coating(s) is between 2% and 60% of the volume of the core particle.
• Figure 1 presents data regarding the release of an active pharmaceutical ingredient from coated microparticles of the invention over a sustained-release period.
• Microparticle means a particle having mean dimension less than 1 mm. Although the microparticles of the invention are substantially spherical in some embodiments, the microparticles can be any solid geometric shape which is not inconsistent with the principles of the invention, including, without limitation, ellipsoids, cylinders, polyhedrons and irregular shapes. Active Pharmaceutical Ingredient. As used herein, the term “active pharmaceutical ingredient” means any compound which has utility as a pharmaceutical or drug, including, without limitation, naturally occurring compounds (e.g., hormones) and synthetic drugs. Core Particle. As used herein, the term “core particle” means a particle comprising the active pharmaceutical ingredient of the invention and which is substantially surrounded or enveloped by the first polymeric coating.
• the core particle can further comprise other compounds, including, without limitation, binders, buffers, antioxidants, excipients, and additional active pharmaceutical ingredients.
• the core particle can be a single large crystal, a multiplicity of crystals, amorphous or non-crystalline material, glassy or hyaline material, or mixtures of the above.
• Sustained Release means continued release of a compound from a reservoir or source over a period of time.
• Parenteral Administration means introduction of a pharmaceutical preparation into the body by a route other than the alimentary canal or digestive tract, including, without limitation, subcutaneous, intravenous, intramuscular and intraocular injection as well as surgical implantation.
• Polymeric Coating means any coating which is formed by polymerization of one or more monomers to form linear or branched or cross-linked macromolecules.
• the coating may be variously characterized as a coating, layer, membrane, shell, capsule, or the like, and must substantially surround or envelope the core particles of the invention.
• Polymer-Forming Solution means a solution including one or more monomers and which is capable of forming a polymeric coating.
• the polymer-forming solution optionally can include one or more solvents which prevent polymerization such that polymerization occurs after removal of the solvents(s). Additionally or in the alternative, the polymer- forming solution optionally can include catalysts or cross-linking agents such that polymerization occurs after removal of solvent(s), heating, or exposure to light or other radiation.
• the polymer-forming solution also can optionally include pore- forming agents.
• Permeable means allowing passage of molecules by diffusion but not by fluid flow.
• Semi-Permeable As used herein, the term “semi-permeable” means permeable to some molecules but not to others. As used herein, semi-permeable polymeric coatings are permeable to at least water and the active pharmaceutical ingredient within the coated microparticles of the invention.
• Biocompatible means characterized by not causing a toxic, injurious or immunological response when brought into contact with living tissue, particularly human or other mammalian tissue.
• Biodegradable means capable of partially or completely dissolving or decomposing in living tissue, particularly human or other mammalian tissue. Biodegradable compounds can be degraded by any mechanism, including, without limitation, hydrolysis, catalysis and enzymatic action. Substantially Degraded. As used herein with respect to polymeric coatings, the term “substantially degraded” means degraded to the degree that approximately 50% of the chemical bonds resulting from polymerization of the polymer-forming solution to form the polymeric coating have been broken.
• Structural Integrity means retaining a continuous surface which is semi-permeable and permits diffusion, but does not include any discontinuities which permit fluid flow.
• external environment means the local area or region of tissue surrounding the coated microparticles of the invention after parenteral administration.
• saturated means containing the maximum concentration of a solute (e.g., an active pharmaceutical ingredient) that can be dissolved at a given temperature.
• substantially insoluble means having a solubiUty of less than 1 part solute per 1000 parts solvent by weight.
• Hydrophobic means having lower affinity for an aqueous solvent than an organic solvent.
• Hydrophilic As used herein, the term “hydrophilic” means having lower affinity for an organic solvent than an aqueous solvent.
• Pseudo-Zero-Order Kinetics As used herein, the term “pseudo-zero-order kinetics” means sustained-release of the active pharmaceutical ingredient which exhibits kinetics which is zero-order (i.e., independent of concentration) or between zero-order and first-order (i.e., proportional to concentration) kinetics over the sustained-release period, where the concentration is based on the total amount of the active pharmaceutical ingredient contained within the coated microparticles. In some embodiments, the release of the active pharmaceutical ingredient exhibits kinetics which are more closely approximate zero-order than first-order kinetics.
• numerical Ranges As used herein, the recitation of a numerical range for a variable is intended to convey that the invention may be practiced with the variable equal to any of the values within that range. Thus, for a variable which is inherently discrete, the variable can be equal to any integer value within the numerical range, including the end-points of the range. Similarly, for a variable which is inherently continuous, the variable can be equal to any real value within the numerical range, including the end-points of the range.
• a variable which is described as having values between 0 and 2 can take the values 0, 1 or 2 if the variable is inherently discrete, and can take the values 0.0, 0.1, 0.01, 0.001, or any other real values > 0 and ⁇ 2 if the variable is inherently continuous.
• the present invention depends, in part, upon the development of coated microparticles which permit the release of an active pharmaceutical ingredient over an extended period of time after parenteral administration.
• the coated microparticles of the invention provide for sustained-release with improved kinetics, including approximately constant or pseudo-zero-order kinetics, over the extended period.
• the diffusion of bodily fluids into the coated microparticles creates a saturated solution of the active pharmaceutical ingredient within the microparticles which acts as a "source” of relatively constant concentration.
• the tissue surrounding the site of administration acts as a "sink” of relatively constant lower concentration.
• the rate of diffusion from the source to the sink remains relatively constant, and approximately linear or pseudo-zero-order kinetics of administration can be achieved until the concentration of the active pharmaceutical ingredient within the microparticle decreases to below saturation.
• the coated microparticles of the invention comprise a core including the active pharmaceutical ingredient, which is encapsulated or coated by a first polymeric coating.
• the first polymeric coating must be semi-permeable so as to permit the diffusion of water and the active pharmaceutical ingredient across the coating, but must not permit the bulk movement of the active pharmaceutical ingredient by fluid flow into the surrounding tissues.
• the first polymeric coating must remain permeable to the active pharmaceutical ingredient during a sustained-release period from administration of the microparticles until the concentration of the active pharmaceutical ingredient contained within the microparticle is unsaturated.
• the core particle may partially or completely dissolve in the polymer-forming solution, resulting in microparticles in which the active pharmaceutical ingredient is interspersed or embedded in a matrix of the polymer as opposed to being coated by the polymer.
• a first polymeric coating can be employed which is formed from a first polymer-forming solution in which the active pharmaceutical ingredient is substantially insoluble.
• the diffusion of the active pharmaceutical ingredient across the first polymeric coating exhibits pseudo-zero-order kinetics during the sustained-release period.
• the first polymeric coating is substantially degraded after the sustained-release period.
• the first polymeric coating maintains structural integrity until after the sustained-release period.
• the coated microparticles of the present invention can be formulated into pharmaceutical preparations for parenteral administration.
• the coated microparticles can be formulated as dry preparations.
• the coated microparticles are suspended in a pharmaceutically acceptable carrier (e.g., water, saline solution, Ringer's solution).
• a pharmaceutically acceptable carrier e.g., water, saline solution, Ringer's solution.
• the administration will be by injection (e.g., subcutaneous, intravenous, intramuscular, intraocular), although the coated microparticles can also be introduced to an open wound site or during surgery (e.g., lavage or irrigation of a wound or surgical site).
• a core particle comprising the active pharmaceutical ingredient is coated with a first polymer- forming solution which forms the first polymeric coating.
• the first polymeric coating can be formed by any methods known in the art, as discussed in detail below. To avoid the problems of the prior art, however, it is desirable to reduce or minimize the dissolution of the active pharmaceutical ingredient in the first polymer-forming solution and the consequent formation of a polymeric coating with the active pharmaceutical ingredient interspersed with the polymeric material. Therefore, in some embodiments, the active pharmaceutical ingredient is substantially insoluble in the first polymer-forming solution.
• the active pharmaceutical ingredient is hydrophobic and the first polymer-forming solution is hydrophilic, whereas, in other embodiments, the active pharmaceutical ingredient is hydrophilic and the first polymer-forming solution is hydrophobic.
• the coated microparticles comprise a second polymeric coating, which is formed from a second polymer-forming solution, and which substantially surrounds or envelopes the first polymeric coating and core particle.
• a second polymeric coating can serve several purposes. First, if the first polymeric coating is structurally weak or is subject to tearing or rupture during parenteral administration, a second polymeric coating can be used to add mechanical support. This objective can be accomplished by employing a second-polymeric coating which is permeable to the active pharmaceutical ingredient, or which is impermeable to the active pharmaceutical ingredient but includes pores through which the first polymeric- coating is in fluid communication with the surrounding fluid environment.
• a second polymeric coating can be used to reduce the rate of release. This objective can be accomplished by employing a second-polymeric coating which is either less permeable to the active pharmaceutical ingredient, or which is impermeable to the active pharmaceutical ingredient but includes pores through which the first polymeric- coating is in fluid communication with the surrounding fluid environment.
• a first polymeric coating can be employed which is formed from a hydrophilic first polymer-forming solution in which the active pharmaceutical ingredient is substantially insoluble.
• a second polymeric coating formed from a hydrophobic second polymer-forming solution can then be employed without dissolving the active pharmaceutical ingredient.
• a first polymeric coating can be formed from a hydrophobic first polymer-forming solution followed by a second polymeric coating formed from a hydrophilic second polymer-forming solution.
• the microparticles comprise a second polymeric coating on the first polymeric coating, which is formed from a second polymer- forming solution, and which is permeable to the active pharmaceutical ingredient during the sustained-release period.
• the second polymeric coating can be substantially degraded before or after the first polymeric coating but, like the first polymeric coating, should remain permeable throughout the sustained-release period. If the permeability of the second polymeric coating to the active pharmaceutical ingredient is less than that of the first polymeric coating, it will act as the rate- controlling coating for determining the rate of release. If the permeability of the second polymeric coating is greater, it will function primarily to provide additional mechanical support of protection to the first polymeric coating.
• the microparticles comprise a porous second polymeric coating on the first polymeric coating, which is formed from a second polymer- forming solution, which defines pore regions which permit fluid communication between a pore portion of the first polymeric coating and the external environment, and which defines non-pore regions which prevent fluid communication between a non-pore portion of the first polymeric coating and the external environment.
• the pores allow diffusion of the active pharmaceutical ingredient across the first polymeric coating in the pore regions, whereas the non-pore region of the second polymeric coating inhibits diffusion of the active pharmaceutical ingredient in the non-pore region.
• the second polymeric coating can be substantially impermeable to the active pharmaceutical ingredient in the non-pore regions.
• the second polymeric coating can reduce the overall rate of release. Moreover, by varying the size of the pore regions, the rate of release can be varied to desired levels. This can be accomplished by including pore-forming agents in the second polymeric coating, and by varying either the identity of the concentration of the pore-forming agents to achieve the desired porosity and, consequently, the desired rate of release.
• the coated microparticles of the invention are intended for parenteral administration.
• the administration will be by injection (e.g., subcutaneous, intravenous, intramuscular, intraocular), although the coated microparticles also can be introduced to a wound site or during surgery (e.g., lavage or irrigation of a wound or surgical site).
• the coated microparticles are sufficiently small to form a suspension and, in some embodiments, the microparticles are sufficiently small for injection through a hypodermic needle.
• the coated microparticles have a maximum dimension of between 20 ⁇ m and 800 ⁇ m, between 40 ⁇ m and 400 ⁇ m, or between 100 ⁇ m and 250 ⁇ m.
• the core particles of the present invention constitute a substantially larger portion of the overall volume and weight of the coated microparticles and, conversely, the polymeric coating(s) constitute a substantially smaller portion.
• a relatively thin polymeric coating can contain a relatively large core which contains a saturated solution of the active pharmaceutical ingredient and permits release by diffusion with pseudo-zero-order kinetics.
• the weight of the polymeric coating(s) is between 0.1% and 200% of the weight of the core particle, or between 2% and 60% of the weight of the core particle.
• the volume of the polymeric coating(s) is between 0.1% and 200% of the volume of the core particle, or between 2% and 60% of the volume of the core particle.
• Standard biocompatible and biodegradable polymeric coatings known in the art can be employed in the present invention to the extent that they meet the requirements described above with respect to retaining permeability and/or structural integrity during the desired sustained-release period.
• the desired sustained-release period can, of course, vary with disease or condition being treated, the nature of the active pharmaceutical ingredient, and the condition of the particular subject to be treated. Thus, the desired sustained-release period can be determined by the attending physician.
• sustained-release period for any given preparation of coated microparticles will depend upon various parameters of the microparticles and the route of administration.
• the sustained-release period will vary depending upon the solubility of the active pharmaceutical ingredient, the rate of clearance of the active pharmaceutical ingredient from the intended site of administration, the size of the core particle and/or the amount of the active pharmaceutical ingredient initially present in the core particle, the presence of other compounds within the core particle that affect the rate of release of the active pharmaceutical ingredient, the permeability of the polymeric coating(s) to the active pharmaceutical ingredient, and the rate of degradation of the polymeric coating(s), as well as other factors.
• both the permeability and biodegradability of polymeric coatings can be affected by the choice of polymeric material (e.g., degree of hydrophobicity or hydrophilicity relative to the active pharmaceutical ingredient; degree of lability of bonds under physiological conditions), degree of cross-Unking and thickness.
• polymeric material e.g., degree of hydrophobicity or hydrophilicity relative to the active pharmaceutical ingredient; degree of lability of bonds under physiological conditions
• the ratio of the different monomers also can be varied to affect permeability and biodegradability.
• pore-forming agents can be used to create pores for fluid communication with the first polymeric coating and, by varying the area of the first polymeric coating which is accessible to the external environment, the average or effective overall permeability of the coated microparticles can be varied.
• biocompatible and biodegradable polymers examples include poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), poly( ⁇ -caprolactone) (PCL), poly(valerolactone) (PVL), poly( ⁇ -decalactone) (PDL), poly(l,4-dioxane-2,3-dione), poly(l,3-dioxane-2-one), poly(para-dioxanone) (PDS), poly(hydroxybutyric acid) (PHB), poly(hydroxy valeric acid) (PHV), and poly( ⁇ -malic acid) (PMLA).
• PLA poly(lactic acid)
• PGA poly(glycolic acid)
• PLA poly(lactic-co-glycolic acid)
• PCL poly( ⁇ -caprolactone)
• PVL poly(valerolactone)
• PVL poly( ⁇ -decalactone)
• PDS poly(
• useful polymers include, without limitation, naturally occurring polymers including carbohydrates such as sugar phosphates, alkylcelluloses (e.g., ethylcellulose), and hydroxyalkylcelluloses (e.g., hydroxypropylcellulose); and synthetic polymers or co-polymers including one or more of the following monomers: lactic acid, glycolic acid, ⁇ -propiolactone, ⁇ -butyrolactone, ⁇ -butyrolactone, pivalolactone, ⁇ -hydroxy butyric acid, ⁇ -hydroxyethyl butyric acid, ⁇ -hydroxy isovaleric acid, ⁇ -hydroxy- ⁇ -methyl valeric acid, ⁇ -hydroxy caproic acid, ⁇ -hydroxy isocaproic acid, ⁇ -hydroxy heptanic acid, ⁇ -hydroxy octanic acid, ⁇ -hydroxy decanoic acid, ⁇ -hydroxy myristic acid, ⁇ -hydroxy stearic acid, ⁇ -hydroxy lignoceric acid, ⁇ -
• Co-polymers offer a degree of flexibility in selecting or designing polymeric coatings with desired properties of permeability and biodegradability because these properties can be controlled by varying the types and relative ratios of co-monomers used.
• PLGA polymers are more hydrophlic than PLA polymers, and the hydrophilicity can be increased by increasing the percentage of glycolic acid in the co- polymer.
• PLGA polymers are more rapidly degraded than PLGA polymers, and the rate of degradation can be decreased by increasing the percentage of lactic acid in the co-polymer.
• polymeric coatings with the desired characteristics can be produced.
• the polymeric coatings can optionaUy be covalently or ionicaUy cross-linked.
• monomers can be chosen which include chemical groups which are capable of forming additional bonds between monomers, or separate cross-linking agents can be included in the polymer- forming solutions in addition to the monomers.
• the cross- linking groups are thermally activated, whereas in other embodiments they are photoactivated, including photoactivation by visible or ultraviolet radiation.
• Cross- linking groups include, without limitation, unsaturated groups such as vinyl, allyl, cinnamate, acrylate, diacrylate, oligoacrylate, methacrylate, dimethacrylate, and oligomethoacrylate groups.
• hydrophilic polymeric coatings include, without limitation, poly( vinyl alcohol) (PVA), poly(ethylene glycol) (PEG), poly(ethylene oxide), poly(vinylpy ⁇ olidone), poly(ethyloxazoline), or polysaccharides or carbohydrates such as alkylcelluloses, hydroxyalkylcelluloses, hyaluronic acid, dextran, heparan sulfate, chondroitin sulfate, heparin, or alginate, or proteins such as gelatin, collagen, albumin, ovalbumin, or polyamino acids.
• PVA poly( vinyl alcohol)
• PEG poly(ethylene glycol)
• PEG poly(ethylene oxide)
• poly(ethyloxazoline) polysaccharides or carbohydrates such as alkylcelluloses, hydroxyalkylcelluloses, hyaluronic acid, dextran, heparan sulfate, chondroitin sulfate,
• hydrophobic polymers include, without limitation, PLA, PGA, PLGA, PCL, poly(alkylene oxides), polyanhydrides (see, e.g., U.S. Pat. No. 4,757,128, U.S. Pat. No. 4,857,311, U.S. Pat. No.4,888,176, and U.S. Pat. No. 4,789,724) and co-polymers thereof.
• a second polymeric coating is employed which is impermeable to the active pharmaceutical ingredient but which includes pores through which the first polymeric coating is accessible to the external environment and through which the active pharmaceutical ingredient can be released. Therefore, in such embodiments, the second polymer-fo ⁇ ning solution can comprise pore-forming agents which dissolve after formation of the second polymeric coating (either in vitro prior to administration, or in vivo after administration).
• Methods of Forming Polymeric Coatings Methods of Forming Polymeric Coatings. Methods of forming polymeric coatings on particles are well known in the art.
• standard techniques include solvent evaporation/extraction techniques, in-water drying techniques (see, e.g., U.S. Pat. No. 4,994,281), organic phase separation techniques (see, e.g., U.S. Pat. No. 4,675,19, U.S. Pat. No. 5,639,480), spray-drying techniques (see, e.g., U.S. Pat. No. 5,651,990), triple emulsion techniques (see, e.g., U.S. Pat. No.4,652,441, U.S. Pat. No. 5,639,480), air suspension techniques, and dip coating techniques.
• a PVA polymeric coating can be applied using a dip coating technique.
• a 1% solution of PVA in water can be formed by dissolving excess PVA in water at 60°C for 2h (see, e.g., Byron and Dalby (1987), /. Pharm. Sci. 76(l):65-67).
• a higher concentration PVA solution e.g., 3-4%
• the microparticles can be added to the PVA solution and agitated by, for example, swirling or stirring. The microparticles are then removed from the solution by, for example, filtration on filter paper with a mesh size appropriate to the microparticles.
• PVA polymeric coatings or films are readUy permeable to water and hydrophilic drugs. Heating of PVA, however, causes an increase in crystallinity and decrease of permeability of up to 500-fold with increasing temperatures in the range of 100-200°C for periods of 0-160 hours (Byron and Dalby (1987), supra).
• PVA polymeric coatings can be heated to temperatures between 100°C and 200°C, between 125°C and 175°C, or between 155°C and 170°C for periods between 1 sec. and 160 hours, between 1 min. and 10 hours, or between 5 minutes and 2 hours.
• the coating process can be repeated several times to build-up a thicker polymeric coating.
• the second polymer-forming solution optionaUy can include pore-forming agents.
• Pore-forming agents include, without limitation, compounds such as sugars (e.g., glucose, sucrose, lactose, saccharose) or salts (e.g., sodium chloride), polyalcohols (e.g., glycerol), organic acids (e.g., citric acid, fumaric acid), and polymers such as hydroxypropyl ceUulose, hydroxypropylmethyl cellulose, polyethylene glycols, and polyvinyl py ⁇ olidones, and mixtures thereof.
• the pore-forming agents can be removed from the coated microparticles prior to administration, or can dissolve in vivo.
• coated microparticles of the invention are administered parenterally.
• the administration is by injection of a suspension of the coated microparticles in a pharmaceutically acceptable carrier, whereas in other embodiments the coated microparticles are administered to an open wound or surgical site.
• Administration by injection includes, without limitation, subcutaneous, intravenous, intramuscular and intraocular injection.
• the coated microparticles must have a maximum dimension which is less than the inner diameter of the needle used for injection.
• larger needles may be employed to accommodate larger coated microparticles, such larger coated microparticles can have decreased ability to form a suspension. Therefore, in some embodiments, the coated microparticles have a maximum dimension less than the inner diameter of standard needles for parenteral injection.
• the coated microparticles can be chosen to have a maximum size which permits formulation as a suspension in a pharmaceutically acceptable carrier.
• the coated microparticles can be administered in a suspension, as described above, or as a solid (e.g., a powder), paste, cream, or ointment.
• the coated microparticles can be administered during lavage or irrigation of a wound or surgical site, and the coated microparticles can be substantially larger.
• Active Pharmaceutical Ingredients are included in the coated microparticles.
• Active pharmaceutical ingredients which may be formulated according to the invention include any active pharmaceutical ingredients or pharmaceutically acceptable salts thereof which may be formulated into coated microparticles of the invention without undergoing chemical alteration or degradation which adversely affects its pharmaceutical utility.
• active pharmaceutical ingredients can be selected from various groups based on the type of agent or type of condition being treated.
• potentially useful active pharmaceutical ingredients can be selected from groups including corticosteroids, anti-psychotics, anti-depressants, anti-epileptics, anti-Parkinson agents, anesthetics, narcotics, antibiotics, HTV protease inhibitors, reverse transcriptase inhibitors, HMG CoA reductase inhibitors, calcium channel blockers, ⁇ -blockers, angiotensin II receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, taxanes, alkylating agents, immunosuppressive agents, hormones and hormone receptor modulators, as well as other active pharmaceutical ingredients for which sustained-release formulations would be advantageous.
• groups including corticosteroids, anti-psychotics, anti-depressants, anti-epileptics, anti-Parkinson agents, anesthetics, narcotics, antibiotics, HTV protease inhibitors, reverse transcriptase inhibitors, HMG CoA reductase inhibitors, calcium channel blockers, ⁇ -
• corticosteroids include dexamefhasone, triamcinolone, fluocinolone, fluocinolone acetonide, cortisone, prednisolone, fluometholone, clobetasone butyrate, triamcinolone acetonide, betamethasone valerate, diflucortolone valerate, fluticasone valerate, hydrocortisone 17-butyrate, mometasone furoate, methylprednisolone acetonate, clobetasol propionate, betamethasone dipropionate, desonide and fluticasone.
• Non-limiting examples of anti-psychotics include benzodiazepines such as olanzapine (ZyprexaTM), clozapine, loxapine, and quetiapine; benzisoxazole derivatives such as risperidone (RisperdalTM) and molindone, and pimozide.
• benzodiazepines such as olanzapine (ZyprexaTM), clozapine, loxapine, and quetiapine
• benzisoxazole derivatives such as risperidone (RisperdalTM) and molindone, and pimozide.
• Non-limiting examples of antidepressants include tertiary amine tricyclics such as amitriptaline, doxepin and imipramine; secondary amine tricycUcs such as desipramine and nortrypitylene; tetracycUcs such as mirtazapine; triazolopyridines such as trazadole; aminoketones such as buproprion; phenethylamines such as venlafaxine; phenylpiperazines such as nefazadone; and selective serotonin reuptake inhibitors (SSRIs) such as citalopram, fluoxetine, fluvoxamine, paroxetine, and sertaline.
• SSRIs selective serotonin reuptake inhibitors
• Non-limiting examples of anti-epileptics include hydantoins such as dilantin; barbiturates such as phenobarbital; deoxybarbiturates such as primidone; iminostilbenes such as cabamazepine; succinimides such as ethosuximide; benzodiazepines such as clonazepam; as well as valproic acid, gabapentin, levetiracetam, tiagabine, topiramate and zonisamide.
• hydantoins such as dilantin
• barbiturates such as phenobarbital
• deoxybarbiturates such as primidone
• iminostilbenes such as cabamazepine
• succinimides such as ethosuximide
• benzodiazepines such as clonazepam
• valproic acid gabapentin, levetiracetam, tiagabine, topiramate and zonisamide.
• Non-limiting examples of anti-Parkinson agents include levodopa preparations such as levodopa benserazide and levodopa/carbidopa; ergot dopamine agonists such as bromocriptine, cabergoline, and pergolide; non-ergot dopamine agonists such pramipexole, ropinerole, and spomorphine; catechol-0-methyltransferase inhibitors such as entacapone and tolcapone; monoamine oxidase B inhibitors such as selegiline; NMDA antagonists such as amantadine; and anticholmergics such as benzhexol, benztropine, biperiden, orphenedrine, and procyclidine.
• levodopa preparations such as levodopa benserazide and levodopa/carbidopa
• ergot dopamine agonists such as bromocriptine, cabergoline
• Non-limiting examples of anesthetics include procaine (NovocainTM), bupivacaine (MarcaineTM), lidocaine (XylocaineTM), etidocaine, ropivacaine, choloroprocaine, tetracaine and mepivacine.
• Non-limiting examples of narcotics include morphine, hydromorphone, meperidine, fentanyl, propoxyphene, levorphanol, codeine, hydrocodone, oxymorphone, levomethadyl acetate, oxycodone and methadone.
• antibiotics include tetracycline antibiotics, such as tetracycline, chlortetracycline, oxytetracycline, demeclocycline, methacycline, doxycycline, and minocycline; penicillin antibiotics such as penicillin, chlorpenicillin, oxypenicillin, methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, ampicillin, amoxicillin, baca picillin, carbenicillin, carbenicillin indanyl, ticarcUlin, mezlociUin and piperacillin; macrolide antibiotics such as erythromycin, clarithromycin and azithromycin; fluoroquinolone antibiotics such as norfloxacin, ciprofloxacin, ofoxacin, sparfloxacin, lomefloxacin, fleroxacin, perfloxacin, levofloxacin, trovafloxacin, gatif
• HTV protease inhibitors include ritonavir, indinavir, nelfinavir, saquinavir, amprenavir and lopinavir.
• nucleoside reverse transcriptase inhibitors include the nucleoside-based reverse transcriptase inhibitors zidovudine, didanosine, stavudine, zalcitabine, lamuvidine, and abacavir, and the non-nucleoside-based reverse transcriptase inhibitors include delavirdine, efavirenez and nevirapine.
• HMG Co-A reductase inhibitors include simvastatin (ZocorTM), lovastatin (MevacorTM), atorvastatin (LipitorTM), pravastatin sodium, fluvastatin and cerivastatin
• Non-limiting examples of calcium channel blockers include dihydropyridines, such as nifedipine; phenyl alkyl amines, such as verapamil; and benzothiazepines, such as diltiazem; as well as amrinone, amlodipine, bencyclane, felodipine, fendiUne, flunarizine, isradipine, nicardipine, nimodipine, perhexilene, gallopamil, tiapamil, phenytoin, barbiturates, dynorphin, omega-conotoxin, and omega-agatoxin.
• dihydropyridines such as nifedipine
• phenyl alkyl amines such as verapamil
• benzothiazepines such as diltiazem
• amrinone amlodipine, bencyclane, felodipine, fendiUne
• Non-limiting examples of ⁇ blockers include propranolol, atenolol, acebutolol, alprenolol, befunolol, betaxolol, bunitrolol, carteolol, ceUprolol, hedroxalol, indenolol, labetalol, levobunolol, mepindolol, methypranol, metindol, metoprolol, metrizoranolol, oxprenolol, pindolol, practolol, sotalolnadolol, tiprenolol, tomalolol, timolol, bupranolol, penbutolol and trimepranol.
• Non-limiting examples of angiotensin II receptor antagonists include saralasin.
• Non-limiting examples of ACE inhibitors captopril, zofenopril, enalapril, lisinopril, quinapril, ramipril, perindopril, cilazapril, benazapril, fosinopril and trandolopril.
• Non-limiting examples of taxanes include paclitaxel and docetaxel.
• Non-Umiting examples of alkylating agents include the nitrogen mustards, alkyl sulfonate, nitrosurea, ethylenimine and methylmelamine, triazene classes, cyclophosphamide, ifosamide, thiotepa, melphalan, busulfan, carmustine, clorambucil, hexamethylmelamine and streptozocin.
• Non-limiting examples of immunosuppressive agents that suppress the immune system includes the corticosteroids, the purine antagonists such as azathioprine, cyclosporine, tacrolimun, sirolimus and mycophenolate mofetil.
• hormones and hormone receptor modulators include insulin, pituitary growth hormone, adrenocorticotrophic hormone, testosterone, progesterone, estrogen, levonorgestrel (NorplantTM), tamoxifen, raloxifen and fulvestrant.
• Non-limiting examples of other active pharmaceutical ingredients potentially useful in the invention include vinca alkaloids such as vincristine and vinblastine; platinum coordination complexes such as cisplatin and carboplatin; isoflavones such as genistein, formomonetin, daidzein and equol; epidophylotoxins such as etoposide and teniposide; camptothecins such as topotecan,and crizecan; folic acid analogues such as methotrexate; pyrimidine analogues such as 5-fluorouracil, floxuridine, and cytosine arabinoside; and purine analogues such as 6-mercaptopurine, 6-thioguanine, and 2-deoxycoformycin; as well as the anti-alcoholism medication disulfiram
• Pressure-fused particles were prepared from the active pharmaceutical ingredient olanzapine, an atypical antipsychotic drug, obtained in micronized form (90% of particles ⁇ 5 ⁇ m in diameter) from a commercial suppUer (Dr. Reddy Labs, Upper Saddle River, NJ).
• the lower punch of a hydraulic press used for producing IR pellets was placed into a die with an 8 mm diameter, and approximately 30 mg of olanzapine was loaded into the die.
• the upper punch was placed into the die, and moderate pressure was applied by hand to pack and evenly distribute the active pharmaceutical ingredient in the die.
• the die assembly was seated in the press and force was increased to 25-30 mtons and maintained for a minimum of 30 seconds, and typically 90 seconds.
• the area of the die was approximately 0.50 cm and, therefore, the pressure was 50-60 mtons/cm .
• the pressure was approximately 5-6 GPa.
• the high pressure compaction produced a "fused" or “glassy” wafer of olanzapine that was removed from the press.
• the compacted sample was then forced through a 60 mesh sieve grating with apertures of approximately 250 ⁇ m to produce roughly cuboidal particles.
• Poly vinyl alcohol (PVA) was obtained with a mol. wt. range of 124,000- 186,000. Excess PVA was heated in water at 65°C. After cooling, the PVA solution was decanted and mixed with core particles prepared as described above. The core particles were swirled in a beaker of the PVA solution for several seconds, and vacuum-filtered onto #42 filter paper (Whatman, Inc., Clifton, NJ) in a 9 cm diameter Buchner funnel. The filter paper with retained coated core particles was transferred to a watch glass and dried at 155°C or 165°C for 10 minutes. This process was repeated 4-5 times.
• #42 filter paper Whatman, Inc., Clifton, NJ
• micronized olanzapine (90% of particles ⁇ 5 ⁇ m in diameter) from a commercial supplier (Dr. Reddy Labs, Upper Saddle River, NJ) was compared with the dissolution of coated microparticles of olanzapine prepared as described above.
• Powder dissolution testing was carried out in distilled water at 25°C. A 2-3 mg sample of the powder in 25 ml of water was 50% dissolved at approximately 1 minute, and was completely dissolved in 2.5 minutes.
• Coated microparticle dissolution testing was also carried out in distilled water at 25°C. A 2-3 mg sample was placed in 25 ml of water. The microparticles were completely covered by the solution. Every 24 h for 5 days, 5 ml of the supernatant solution was carefully removed and replaced with fresh media, avoiding mixing of the buffer, to simulate physiological "sink” conditions.
• Figure 1 represents the data regarding the release of the active pharmaceutical ingredient from the coated microparticles over time. As shown in the figure, the rate of release was substantially constant or pseudo-zero-order over several days. The release rate from the PVA- coated microparticles dried at the lower temperature was greater, indicating that drying temperature can be used to vary permeability and release rate.
• HPLC high performance liquid chromatography

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (5)

Applications Claiming Priority (70)

Publications (1)

Family

ID=32686487

Family Applications (2)

Family Applications After (1)

Country Status (3)

Cited By (5)

Families Citing this family (3)

Citations (5)

Family Cites Families (2)

• 2003
  • 2003-12-22 WO PCT/US2003/041391 patent/WO2004058223A1/en active Application Filing
  • 2003-12-22 AU AU2003299983A patent/AU2003299983A1/en not_active Abandoned
  • 2003-12-22 WO PCT/US2003/041392 patent/WO2004058222A1/en active Application Filing
  • 2003-12-22 AU AU2003299982A patent/AU2003299982B2/en not_active Expired
  • 2003-12-22 EP EP03800248A patent/EP1583519A1/de active Pending
• 2010
  • 2010-03-23 AU AU2010201138A patent/AU2010201138A1/en not_active Abandoned

Patent Citations (5)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events